U.S. In Vivo Cro Market Size & Outlook, 2023-2030
U.S. in vivo cro market, 2018-2030 (US$M)
Related Markets
U.S. in vivo cro market highlights
- The U.S. in vivo cro market generated a revenue of USD 1,726.4 million in 2023 and is expected to reach USD 3,003.9 million by 2030.
- The U.S. market is expected to grow at a CAGR of 8.2% from 2024 to 2030.
- In terms of segment, small molecule was the largest revenue generating modality type in 2023.
- Large Molecule is the most lucrative modality type segment registering the fastest growth during the forecast period.
In vivo cro market data book summary
| Market revenue in 2023 | USD 1,726.4 million |
| Market revenue in 2030 | USD 3,003.9 million |
| Growth rate | 8.2% (CAGR from 2023 to 2030) |
| Largest segment | Small molecule |
| Fastest growing segment | Large Molecule |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Small Molecule, Large Molecule |
| Key market players worldwide | IQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group |
Other key industry trends
- In terms of revenue, U.S. accounted for 37.4% of the global in vivo cro market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. in vivo cro market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 3,003.9 million by 2030.
Small molecule was the largest segment with a revenue share of 63.64% in 2023. Horizon Databook has segmented the U.S. in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
Pharmaceutical and biotech companies across Europe and Asia are increasingly outsourcing in vivo activities to the U.S.-based CROs to enter the U.S. market. The U.S.-based CROs offer high-quality services, scientific expertise, and an increasing number of partnerships, making them an excellent choice for these companies. In addition, the patent expiry is another factor encouraging the adoption of U.S.-based CROs.
This, in turn, is expected to fuel the in vivo CRO market growth. However, stringent regulatory scenarios and cost containment pressure may pose challenges for the market in the U.S. Furthermore, the U.S. has a robust pharmaceutical and biotechnology industry that continuously focuses on drug discovery and development.
This emphasis has improved the demand for in vivo CRO services, as these organizations play a crucial role in conducting preclinical and clinical research. Several pharmaceutical companies have increasingly outsourced various aspects of their Research and Development (R&D) activities to cater to the growing demand, including preclinical testing.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
In Vivo CRO Market Scope
In Vivo CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. in vivo cro market size, by modality type, 2018-2030 (US$M)
U.S. In Vivo CRO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
